Updates

Bruker Daltonics Announces Contract for Its RAID(TM)-S Shipboard Chemical-Agent Detectors from Major Navy on Indian Subcontinent

LEIPZIG, Germany - The Chemical,  Biological, Radiation and Nuclear (CBRN) detection business of Bruker  Daltonik GmbH in Leipzig, Germany today announces that it has received a  Euro 3.5 million ($ 4.7 million) contract award for its RAID(TM)-S  chemical agent detectors from a major navy on the Indian Subcontinent. Bruker Daltonics is expected to deliver and integrate its RAID-S  detectors in the second half of 2007 and the first half of 2008 in order  to provide real-time chemical agent detection capabilities on board navy  vessels of various es. The contract also includes a multiyear  maintenance contract.  Mr. Sebastian Meyer-Plath, Vice President for CBRN Detection at Bruker Daltonics, commented: "We are very pleased with our selection. This contract is more evidence that the RAID-S has arguably become the most  advanced shipboard chemical agent detector in the world today with detection performance and interference rejection second-to-none. This  contract extends our RAID-S users list by another major blue water navy." About Bruker BioSciences (NASDAQ: BRKR)Bruker BioSciences Corporation, headquartered in Billerica,  Massachusetts, is the publicly traded parent company of Bruker Daltonics  Inc., Bruker AXS Inc. and Bruker Optics Inc. For more information, please  visit www.bruker-biosciences.com  For more information, contact:Bruker BioSciences CorporationMichael Willett, Investor Relations OfficerPhone: (978) 663-3660 ext.  1411Email: Michael.Willett@Bruker.comCautionary Statement Any statements contained in this press release that do not describe  historical facts may constitute forward-looking statements as that term is  defined in the Private Securities Litigation Reform Act of 1995. Any  forward-looking statements contained herein are based on current  expectations, but are subject to a number of risks and uncertainties. The  factors that could cause actual future results to differ materially from  current expectations include, but are not limited to, risks and  uncertainties relating to the companies' reorganization strategies,  integration risks, failure of conditions, technological approaches,  product development, market acceptance, cost and pricing of the companies'  products, changes in governmental regulations, capital spending and  government funding policies, FDA and other regulatory approvals to the  extent applicable, competition, the intellectual property of others,  patent protection and litigation. These and other factors areentified  and described in more detail in our filings with the SEC, including,  without limitation, our respective annual reports on Form 10-K for the  year ended December 31, 2006, our most recent quarterly reports on Form  10-Q, our current reports on Form 8-K and the joint proxy  statement/prospectus filed in connection with the merger. We disclaim any  intent or obligation to update these forward-looking statements.